Literature DB >> 34268452

The excess insulin requirement in severe COVID-19 compared to non-COVID-19 viral pneumonitis is related to the severity of respiratory failure and pre-existing diabetes.

Sam M Lockhart1,2,3, Harry Griffiths3, Bogdan Petrisor3, Ammara Usman3, Julia Calvo-Latorre2, Laura Heales3, Vishakha Bansiya2, Razeen Mahroof3, Andrew Conway Morris3,4.   

Abstract

Introduction: Severe COVID-19 has been anecdotally associated with high insulin requirements. It has been proposed that this may be driven by a direct diabetogenic effect of the virus that is unique to SARS-CoV-2, but evidence to support this is limited. To explore this, we compared insulin requirements in patients with severe COVID-19 and non-COVID-19 viral pneumonitis.
Methods: This is a retrospective cohort study of patients with severe COVID-19 admitted to our intensive care unit between March and June 2020. A historical control cohort of non-COVID-19 viral pneumonitis patients was identified from routinely collected audit data.
Results: Insulin requirements were similar in patients with COVID-19 and non-COVID-19 viral pneumonitis after adjustment for pre-existing diabetes and severity of respiratory failure. Conclusions: In this single-centre study, we could not find evidence of a unique diabetogenic effect of COVID-19. We suggest that high insulin requirements in this disease relate to its propensity to cause severe respiratory failure in patients with pre-existing metabolic disease.
© 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID‐19; diabetes; insulin resistance; stress hyperglycaemia

Mesh:

Substances:

Year:  2021        PMID: 34268452      PMCID: PMC7995054          DOI: 10.1002/edm2.228

Source DB:  PubMed          Journal:  Endocrinol Diabetes Metab        ISSN: 2398-9238


  16 in total

1.  Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany.

Authors:  Clemens Kamrath; Kirsten Mönkemöller; Torben Biester; Tilman R Rohrer; Katharina Warncke; Johanna Hammersen; Reinhard W Holl
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

2.  New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K.

Authors:  Rebecca Unsworth; Susan Wallace; Nick S Oliver; Shunmay Yeung; Archana Kshirsagar; Harshini Naidu; Ruth Min Wai Kwong; Priya Kumar; Karen M Logan
Journal:  Diabetes Care       Date:  2020-08-17       Impact factor: 19.112

3.  Insulin Use, Diabetes Control, and Outcomes in Patients with COVID-19.

Authors:  Shayan Riahi; Lorenna Rodrigues Silva Sombra; Kevin Bryan Lo; Shireen R Chacko; Alvaro Goncalves Mendes Neto; Zurab Azmaiparashvili; Gabriel Patarroyo-Aponte; Janani Rangaswami; Catherine Anastasopoulou
Journal:  Endocr Res       Date:  2020-12-04       Impact factor: 1.720

4.  Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States.

Authors:  Bruce Bode; Valerie Garrett; Jordan Messler; Raymie McFarland; Jennifer Crowe; Robby Booth; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2020-05-09

5.  Management of diabetes in patients with COVID-19.

Authors:  Adrian Li; Sophie Harris; Dulmini Kariyawasam; Dipesh C Patel; Stephen M Thomas
Journal:  Lancet Diabetes Endocrinol       Date:  2020-08       Impact factor: 32.069

6.  New-Onset Diabetes in Covid-19.

Authors:  Francesco Rubino; Stephanie A Amiel; Paul Zimmet; George Alberti; Stefan Bornstein; Robert H Eckel; Geltrude Mingrone; Bernhard Boehm; Mark E Cooper; Zhonglin Chai; Stefano Del Prato; Linong Ji; David Hopkins; William H Herman; Kamlesh Khunti; Jean-Claude Mbanya; Eric Renard
Journal:  N Engl J Med       Date:  2020-06-12       Impact factor: 91.245

Review 7.  Practical recommendations for the management of diabetes in patients with COVID-19.

Authors:  Stefan R Bornstein; Francesco Rubino; Kamlesh Khunti; Geltrude Mingrone; David Hopkins; Andreas L Birkenfeld; Bernhard Boehm; Stephanie Amiel; Richard Ig Holt; Jay S Skyler; J Hans DeVries; Eric Renard; Robert H Eckel; Paul Zimmet; Kurt George Alberti; Josep Vidal; Bruno Geloneze; Juliana C Chan; Linong Ji; Barbara Ludwig
Journal:  Lancet Diabetes Endocrinol       Date:  2020-04-23       Impact factor: 32.069

8.  Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes.

Authors:  Bo Yu; Chenze Li; Yang Sun; Dao Wen Wang
Journal:  Cell Metab       Date:  2020-11-23       Impact factor: 27.287

9.  COVID-19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients.

Authors:  Linda Wu; Christian M Girgis; Ngai Wah Cheung
Journal:  Clin Endocrinol (Oxf)       Date:  2020-08-07       Impact factor: 3.523

10.  Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration.

Authors:  Gian Paolo Fadini; Mario Luca Morieri; Federico Boscari; Paola Fioretto; Alberto Maran; Luca Busetto; Benedetta Maria Bonora; Elisa Selmin; Gaetano Arcidiacono; Silvia Pinelli; Filippo Farnia; Daniele Falaguasta; Lucia Russo; Giacomo Voltan; Sara Mazzocut; Giorgia Costantini; Francesca Ghirardini; Silvia Tresso; Anna Maria Cattelan; Andrea Vianello; Angelo Avogaro; Roberto Vettor
Journal:  Diabetes Res Clin Pract       Date:  2020-08-15       Impact factor: 5.602

View more
  2 in total

1.  Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set.

Authors:  Andrew Conway Morris; Katharina Kohler; Thomas De Corte; Maurizio Cecconi; Jan De Waele; Ari Ercole; Harm-Jan De Grooth; Paul W G Elbers; Pedro Povoa; Rui Morais; Despoina Koulenti; Sameer Jog; Nathan Nielsen; Alasdair Jubb
Journal:  Crit Care       Date:  2022-08-03       Impact factor: 19.334

Review 2.  COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; M Alblihed; Susana G Guerreiro; Natália Cruz-Martins; Gaber El-Saber Batiha
Journal:  Front Cardiovasc Med       Date:  2021-05-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.